Latest Pharmaceutical Innovation News

Noxopharm’s Sofra™ oligonucleotides, delivered via InhaTarget’s inhalable lipid nanoparticles, achieved a significant reduction in lung inflammation in preclinical models, broadening Sofra’s therapeutic reach and delivery versatility.

Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.